Glaxosmithkline Stock News

A Covid-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology was effective against the Omicron variant in early laboratory studies.

This fool assesses GlaxoSmithKline stock for his long-term portfolio after a new Covid drug received the green light for use in the UK. The post Is GlaxoSmithKline stock the best Covid pharma pick? appeared first on The Motley Fool UK .

Futures Rebound Fizzles On Slowing iPhone Demand, Omicron Fears U.S. index futures regained some ground alongside Asian markets while European stocks slumped to session lows in a delayed response to yesterday''s late Omicron-driven US selloff, as markets remained volatile following the biggest two-day plunge in more than a year, spurred by concern about the omicron coronavirus variant and Federal Reserve tightening. Investors await data for unemployment claims, as well as earnings from companies including Dollar General and Kroger. Tech is the weakest sector, dropping in sympathy after Apple warned its suppliers of slowing iPhone demand. Nasdaq futures pared earlier gains of up to 0.8% to trade down 0.1% while S&P futures are only 0.2% higher after rising as much as 0.9%. While the knee-jerk reaction of stock investors may continue to be to take profits before the end of the year, there is plenty of liquidity available to drive stock prices higher as dip-buyers enter the market , Ed Yardeni wrote in a note.

Pharma giant GlaxoSmithKline said on Thursday that an antibody cocktail it developed with a U.S. biotech company has proven in lab testing to be effective against the Omicron coronavirus variant.

GlaxoSmithKline (GSK) has said that its coronavirus drug called sotrovimab is effective against the Omicron variant.

Pharmaceutical giant GlaxoSmithKline (GSK) have had a new Covid drug approved in the UK which works against Omicron and can cut the risk of death by 79%. the Medicines and The post New GSK Covid drug approved in UK cuts risk of death by 79% against Omicron variant appeared first on London Business News | Londonlovesbusiness.com .

LONDON: British regulators on Thursday approved a GlaxoSmithKline drug to treat those at high risk of developing severe Covid-19 symptoms, with the manufacturer saying it appears effective against the new Omicron variant. The antibody treatment, sotrovimab, "was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease," said the Medicines and Healthcare products Regulatory Agency (MHRA). Preclinical data showed that the drug "retains activity against key mutations of the new Omicron SARS-CoV-2 variant," GlaxoSmithKline (GSK) said in a statement. First known UAE case of Omicron variant detected in fully vaccinated traveller "To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO)," it added. Testing is ongoing "to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021." A single dose of the drug was found to reduce the risk of hospitalisation and death by 79 percent in high-risk adults with symptomatic COVID-19 infection, according to the MHRA.

Ellevest Inc. boosted its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 320.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,550 shares of the pharmaceutical companys stock after purchasing an additional 7,277 shares during the period. Ellevest Inc.s holdings in GlaxoSmithKline were []

GLAXOSMITHKLINE PLC - Total Voting Rights PR Newswire London, December 1 GlaxoSmithKline plc Total Voting Rights and Capital In conformity with the Financial Conduct Authority''s Disclosure Guidanc

List of the Companies Operating in the Market: GlaxoSmithKline plc (U.K, Europe), Johnson & Johnson Inc (New Jersey, U.S), Perrigo Company plc (Ireland, Europe), Pierre Fabre SA, Laboratories (France, Europe), Pfizer Inc. (New York, United States), Cipla Limited (Mumbai, India), British American Tobacco Plc (U.K, Europe), Other Players List of the Companies Operating in the Market: GlaxoSmithKline plc (U.K, Europe), Johnson & Johnson Inc (New Jersey, U.S), Perrigo Company plc (Ireland, Europe), Pierre Fabre SA, Laboratories (France, Europe), Pfizer Inc. (New York, United States), Cipla Limited (Mumbai, India), British American Tobacco Plc (U.K, Europe), Other Players

GlaxoSmithKline has poached a Pfizer vaccine executive after failing to bring its own Covid jab to market during the pandemic.

Philip Dormitzer, who was one of the executives involved in the development of Pfizer Inc.''s coronavirus vaccine, is set to join GlaxoSmithKline plc (GSK) as global head of vaccines research and d

Sage Rhino Capital LLC raised its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 7.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,337 shares of the pharmaceutical companys stock after acquiring an additional 454 shares during the quarter. Sage Rhino Capital LLCs []

Inflammation is a process by which your body''s white blood cells and the things they make protect you from infection from outside invaders, such as bacteria and viruses. Although it is not proven that inflammation causes cardiovascular disease, inflammation is